amsacrine has been researched along with Lung Neoplasms in 64 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 7.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| "Amsacrine is a DNA intercalating agent with antineoplastic properties in lymphoproliferative disorders." | 5.27 | Bacterial and mammalian cell mutagenesis, sister-chromatid exchange, and mouse lung adenoma bioassay with the antineoplastic acridine derivative amsacrine. ( de la Iglesia, FA; Fitzgerald, JE; Heifetz, CL; Kim, SN; McGuire, EJ; Stoner, GD, 1984) |
| "To better understand the molecular basis for the cytotoxic effects of suramin, we have developed suramin-resistant DC-3F/SU 1000 cells by continuous exposure of fibrosarcoma cells to increasing concentrations of suramin." | 3.69 | Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. ( Benchokroun, Y; Larsen, AK; Lelièvre, S, 1995) |
| "The cytotoxicity of a class of compounds related to the topoisomerase-II poison amsacrine was investigated against plateau-phase murine Lewis lung carcinoma cells (LLTC), HCT-8 human colon carcinoma cells and other cell lines." | 3.69 | Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. ( Baguley, BC; Finlay, GJ; Holdaway, KM, 1994) |
| " The effect of DACA on the cytokinetics of cultured Lewis lung adenocarcinoma cells was compared with those of two clinical drugs of this class, doxorubicin and amsacrine." | 3.68 | Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin. ( Baguley, BC; Finlay, GJ; Haldane, A; Holdaway, KM, 1993) |
| "The coumermycin antibiotic novobiocin, which interacts with the nuclear enzyme topoisomerase II, produced supra-additive toxicity to WEHI-3B D+ leukemia cells at clinically achievable concentrations, when combined with teniposide (VM-26) or etoposide (VP-16)." | 3.68 | Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26). ( Lorico, A; Rappa, G; Sartorelli, AC, 1992) |
| " Its hydrochloride salt, 13a·HCl exhibited not only excellent water solubility (1049 μg/mL) but also a high oral bioavailability (57." | 1.37 | Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers. ( Chen, YL; Chen, YW; Liang, CC; Lu, PJ; Tseng, CH; Tzeng, CC; Yang, CN; Yao, YC, 2011) |
| "Pretreatment with paclitaxel or vinblastine, but not navelbine, sensitized the subline to cisplatin and chlorambucil (P < 0." | 1.31 | Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle. ( Davey, M; Davey, R; Locke, V, 2001) |
| "We describe a patient with acute renal failure resulting from bilateral infiltration of the kidneys by metastases secondary to small cell lung cancer." | 1.31 | Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration. ( Smith, IE; Stebbing, J, 2000) |
| "Amsacrine is a DNA intercalating agent with antineoplastic properties in lymphoproliferative disorders." | 1.27 | Bacterial and mammalian cell mutagenesis, sister-chromatid exchange, and mouse lung adenoma bioassay with the antineoplastic acridine derivative amsacrine. ( de la Iglesia, FA; Fitzgerald, JE; Heifetz, CL; Kim, SN; McGuire, EJ; Stoner, GD, 1984) |
| "Leukopenia was the dose-limiting toxicity with 7." | 1.27 | The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. ( Amrein, PC; Carey, RW; Coleman, M; Green, MR; Holland, JF; Kennedy, BJ; Poulin, RF; Richards, F; Weil, M; Weinberg, V, 1984) |
| "The antitumor activity and toxic effect of AMSA were studied in Lewis lung carcinoma (3LL) at various stages of growth." | 1.27 | Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma. ( Badaracco, G; Greco, C; Zupi, G, 1983) |
| " Although intraperitoneal dosage was superior to intravenous or oral dosage for the treatment of intraperitoneally inoculated P388 leukaemia, all three routes of administration provided similar results with intravenously inoculated Lewis lung or subcutaneously implanted P388 cells." | 1.27 | Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma. ( Baguley, BC; Grimwade, CD; Kernohan, AR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 34 (53.13) | 18.7374 |
| 1990's | 23 (35.94) | 18.2507 |
| 2000's | 5 (7.81) | 29.6817 |
| 2010's | 1 (1.56) | 24.3611 |
| 2020's | 1 (1.56) | 2.80 |
| Authors | Studies |
|---|---|
| Atwell, GJ | 3 |
| Rewcastle, GW | 3 |
| Baguley, BC | 22 |
| Denny, WA | 5 |
| Spicer, JA | 1 |
| Gamage, SA | 1 |
| Finlay, GJ | 13 |
| Stanslas, J | 1 |
| Hagan, DJ | 1 |
| Ellis, MJ | 1 |
| Turner, C | 1 |
| Carmichael, J | 2 |
| Ward, W | 1 |
| Hammonds, TR | 1 |
| Stevens, MF | 1 |
| Bu, X | 1 |
| Deady, LW | 1 |
| Chen, YW | 1 |
| Chen, YL | 1 |
| Tseng, CH | 1 |
| Liang, CC | 1 |
| Yang, CN | 1 |
| Yao, YC | 1 |
| Lu, PJ | 1 |
| Tzeng, CC | 1 |
| Drummond, CJ | 1 |
| Chen, YY | 1 |
| Creech, RH | 2 |
| Tritchler, D | 1 |
| Ettinger, DS | 2 |
| Ferraro, JA | 2 |
| Ruckdeschel, JC | 2 |
| Vogl, SE | 2 |
| Woll, J | 1 |
| Dady, PJ | 1 |
| Sappino, AP | 1 |
| Rudd, A | 1 |
| Smith, IE | 2 |
| Natale, RB | 1 |
| Gralla, RJ | 1 |
| Wittes, RE | 1 |
| Day, R | 1 |
| Woll, JE | 1 |
| de la Iglesia, FA | 1 |
| Fitzgerald, JE | 1 |
| McGuire, EJ | 1 |
| Kim, SN | 1 |
| Heifetz, CL | 1 |
| Stoner, GD | 1 |
| Amrein, PC | 2 |
| Poulin, RF | 2 |
| Coleman, M | 2 |
| Richards, F | 2 |
| Weil, M | 1 |
| Kennedy, BJ | 2 |
| Carey, RW | 2 |
| Green, MR | 2 |
| Holland, JF | 1 |
| Weinberg, V | 1 |
| Twigden, SJ | 1 |
| Wilson, WR | 6 |
| Greco, C | 1 |
| Zupi, G | 1 |
| Badaracco, G | 1 |
| Berkowitz, I | 1 |
| Green, M | 1 |
| Herschkopf, R | 1 |
| Rafla, S | 1 |
| Kernohan, AR | 2 |
| Vorobiof, DA | 1 |
| Iturralde, M | 1 |
| Falkson, G | 1 |
| Nichols, WC | 1 |
| Eagan, RT | 1 |
| Frytak, S | 1 |
| Ingle, JN | 1 |
| Creagan, ET | 1 |
| Kvols, LK | 1 |
| Stephens, TC | 1 |
| Peacock, JH | 1 |
| Ahmann, FR | 1 |
| Meyskens, FL | 1 |
| Moon, TE | 1 |
| Durie, BG | 1 |
| Salmon, SE | 1 |
| Lelièvre, S | 1 |
| Benchokroun, Y | 1 |
| Larsen, AK | 1 |
| Gromova, II | 1 |
| Thomsen, B | 1 |
| Razin, SV | 1 |
| Eijdems, EW | 1 |
| de Haas, M | 1 |
| Timmerman, AJ | 1 |
| Van der Schans, GP | 1 |
| Kamst, E | 1 |
| de Nooij, J | 1 |
| Astaldi Ricotti, GC | 1 |
| Borst, P | 1 |
| Baas, F | 1 |
| Prost, S | 1 |
| Riou, G | 2 |
| Jensen, PB | 3 |
| Sørensen, BS | 2 |
| Sehested, M | 3 |
| Grue, P | 1 |
| Demant, EJ | 2 |
| Hansen, HH | 2 |
| Holdaway, KM | 2 |
| Haldane, A | 2 |
| de Jong, S | 2 |
| Kooistra, AJ | 1 |
| de Vries, EG | 3 |
| Mulder, NH | 3 |
| Zijlstra, JG | 2 |
| Kirk, J | 1 |
| Houlbrook, S | 1 |
| Stuart, NS | 1 |
| Stratford, IJ | 2 |
| Harris, AL | 1 |
| Withoff, S | 1 |
| Keith, WN | 1 |
| Nienhuis, EF | 1 |
| van der Graaf, WT | 1 |
| Uges, DR | 1 |
| Maurer, LH | 1 |
| Herndon, JE | 1 |
| Hollis, DR | 1 |
| Aisner, J | 1 |
| Skarin, AT | 1 |
| Perry, MC | 1 |
| Eaton, WL | 1 |
| Zacharski, LL | 1 |
| Hammond, S | 1 |
| Laurençot, CM | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Shoemaker, RH | 1 |
| Bridewell, DJ | 1 |
| Wessel, I | 1 |
| Jensen, LH | 1 |
| Falck, J | 1 |
| Rose, A | 1 |
| Roerth, M | 1 |
| Nitiss, JL | 1 |
| Qian, W | 1 |
| Parmar, MK | 1 |
| Sambrook, RJ | 1 |
| Fayers, PM | 1 |
| Girling, DJ | 1 |
| Stephens, RJ | 1 |
| Locke, V | 1 |
| Davey, R | 1 |
| Davey, M | 1 |
| Stebbing, J | 1 |
| Pommier, Y | 1 |
| Orr, A | 1 |
| Kohn, KW | 1 |
| Riou, JF | 2 |
| Rappa, G | 1 |
| Lorico, A | 1 |
| Sartorelli, AC | 1 |
| Gavin, JB | 1 |
| Harvey, VJ | 2 |
| Hardy, JR | 1 |
| Smith, S | 1 |
| Grove, W | 1 |
| Jensen, PS | 1 |
| Vindeløv, L | 1 |
| Kestell, P | 1 |
| Paxton, JW | 1 |
| Evans, PC | 1 |
| Young, D | 1 |
| Jurlina, JL | 1 |
| Robertson, IG | 1 |
| Hanauske, AR | 2 |
| Hanauske, U | 1 |
| Von Hoff, DD | 3 |
| Multon, E | 1 |
| LeFevre, D | 1 |
| Ahomadegbe, JC | 1 |
| Lathan, B | 1 |
| Clark, GM | 1 |
| Elslager, EE | 1 |
| West, CM | 1 |
| Denstman, SC | 1 |
| Ervin, SJ | 1 |
| Casero, RA | 1 |
| Kramer, BS | 1 |
| Birch, R | 1 |
| Einhorn, L | 1 |
| Greco, A | 1 |
| Perry, DJ | 1 |
| Weiss, RB | 1 |
| Hoth, DF | 1 |
| Calveley, SB | 1 |
| Leopold, WR | 1 |
| Corbett, TH | 1 |
| Griswold, DP | 1 |
| Plowman, J | 1 |
| Long, BH | 1 |
| Musial, ST | 1 |
| Brattain, MG | 1 |
| Grimwade, CD | 1 |
| Louie, AC | 1 |
| Issell, BF | 1 |
4 reviews available for amsacrine and Lung Neoplasms
| Article | Year |
|---|---|
DNA-Binding Anticancer Drugs: One Target, Two Actions.
Topics: Adenocarcinoma of Lung; Amsacrine; Anaphase; Animals; Antineoplastic Agents; Chromatids; Chromosome | 2021 |
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Topics: Aminoacridines; Amsacrine; Animals; Anthracenes; Antineoplastic Agents; Blood Physiological Phenomen | 1985 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
6 trials available for amsacrine and Lung Neoplasms
| Article | Year |
|---|---|
Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcin | 1984 |
A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.
Topics: Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bron | 1983 |
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 1997 |
Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Data I | 2000 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
56 other studies available for amsacrine and Lung Neoplasms
| Article | Year |
|---|---|
Potential antitumor agents. 48. 3'-Dimethylamino derivatives of amsacrine: redox chemistry and in vivo solid tumor activity.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chemical Phenomena; Chemistry; Colo | 1987 |
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Enzyme Inhibitors; Leuk | 1997 |
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, | 2000 |
Synthesis and cytotoxic activity of 7-oxo-7H-dibenz[f,ij]isoquinoline and 7-oxo-7H-benzo[e]perimidine derivatives.
Topics: Animals; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; Doxorubicin; Drug Design; Drug Res | 2001 |
Discovery of 4-anilinofuro[2,3-b]quinoline derivatives as selective and orally active compounds against non-small-cell lung cancers.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-S | 2011 |
A phase II clinical study of mAMSA in small cell carcinoma of the lung.
Topics: Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Drug Evaluation; Fema | 1981 |
A phase II trial of m-AMSA in patients with small-cell lung cancer.
Topics: Aged; Aminoacridines; Amsacrine; Bone Marrow; Carcinoma, Small Cell; Dose-Response Relationship, Dru | 1981 |
Bacterial and mammalian cell mutagenesis, sister-chromatid exchange, and mouse lung adenoma bioassay with the antineoplastic acridine derivative amsacrine.
Topics: Adenoma; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Biological Assay; Cricetinae; Cr | 1984 |
The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leuk | 1984 |
Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cattle; Cell Division; Cell Line; Cell Su | 1984 |
Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.
Topics: Aminoacridines; Amsacrine; Animals; Drug Administration Schedule; Female; Hematopoiesis; Leukopenia; | 1983 |
Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Drug Evaluation; Female; Humans | 1983 |
Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Drug Admin | 1983 |
Amsacrine cardiotoxicity: assessment of ventricular function by radionuclide angiography.
Topics: Aged; Aminoacridines; Amsacrine; Angiography; Antineoplastic Agents; Dose-Response Relationship, Dru | 1983 |
Phase II evaluation of AMSA in patients with metastatic lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma, Squamous C | 1980 |
Clonal variation in the sensitivity of B16 melanoma to m-AMSA.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; Clone Cells; Lung Neoplasm | 1982 |
In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cells, Cultured; Drug Evaluation; Female; Genital | 1982 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; | 1995 |
Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Topics: Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Cell Fractionation; Cell Line; Cell Nucleus | 1995 |
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Topics: Amsacrine; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; Dr | 1995 |
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Topics: Amsacrine; Base Sequence; Camptothecin; Carcinoma, Small Cell; DNA Primers; DNA Topoisomerases, Type | 1994 |
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Topics: Amsacrine; Animals; Carcinoma, Small Cell; Chloroquine; DNA Damage; DNA Topoisomerases, Type II; DNA | 1994 |
Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
Topics: Amsacrine; Animals; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance; | 1994 |
Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
Topics: Acridines; Adenocarcinoma; Amsacrine; Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Doxorubicin; | 1993 |
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Topics: Amsacrine; Carcinoma, Small Cell; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug | 1993 |
Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
Topics: Amsacrine; Animals; Breast Neoplasms; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Dose-Response | 1993 |
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Topics: Amsacrine; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding | 1996 |
Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines.
Topics: Amsacrine; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Nucleus; Cisplatin; Coloni | 1997 |
Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; | 1999 |
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineopla | 1999 |
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Survival; Ch | 2001 |
Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration.
Topics: Acute Kidney Injury; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cel | 2000 |
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Topics: Amsacrine; Animals; Base Sequence; Binding Sites; Carcinoma, Small Cell; Cell Line; DNA Damage; DNA | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA T | 1992 |
Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
Topics: Acridines; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Death; Cell Survival; DNA | 1992 |
Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Fema | 1991 |
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Benzimidazoles; Bisbenzimidazole; Colonic Neop | 1990 |
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Cycl | 1990 |
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Topics: Aclarubicin; Amsacrine; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin | 1990 |
Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carcinoma; Liver; Lung Neoplasms; Male; Metabolic Clearan | 1990 |
Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Topics: Alkaloids; Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cell Line; DNA; D | 1989 |
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.
Topics: Acridines; Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Cell Survival; Dose-Response R | 1989 |
Evaluation of an amsacrine analog in a human tumor cloning system.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Resistance; Humans; Lung | 1989 |
A comparison of adriamycin and mAMSA. II. Studies with V79 and human tumour multicellular spheroids.
Topics: Amsacrine; Animals; Carcinoma, Small Cell; Cell Survival; Cricetinae; Cricetulus; Dose-Response Rela | 1987 |
Comparison of the effects of treatment with the polyamine analogue N1,N8 bis(ethyl)spermidine (BESpd) or difluoromethylornithine (DFMO) on the Topoisomerase II mediated formation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA) induced cleavabl
Topics: Amsacrine; Chemical Precipitation; DNA Topoisomerases, Type II; DNA, Neoplasm; Eflornithine; Humans; | 1987 |
Phase II evaluation of amsacrine in small cell lung cancer: a Southeastern Cancer Study Group trial.
Topics: Aminoacridines; Amsacrine; Carcinoma, Small Cell; Drug Evaluation; Humans; Leukocyte Count; Lung Neo | 1985 |
Hypersensitivity reactions to amsacrine.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Carcinoma, Squamous Cell; | 1985 |
Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma.
Topics: Amsacrine; Animals; Antineoplastic Agents; Ascorbic Acid; Drug Evaluation, Preclinical; Lung Neoplas | 1988 |
Effects of CI-921, an analogue of amsacrine, on advanced Lewis lung tumours in mice: relevance to clinical trials.
Topics: Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Flow Cytometry; Lung; L | 1988 |
Cytokinetic factors in drug resistance of Lewis lung carcinoma: comparison of cells freshly isolated from tumours with cells from exponential and plateau-phase cultures.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Resistance; Interphase; | 1987 |
In vitro and in vivo assessment of activity of new anilino-substituted analogues of amsacrine against Lewis lung carcinoma.
Topics: Amsacrine; Animals; DNA; Female; Lung Neoplasms; Mice; Mice, Inbred DBA; Neoplasms, Experimental; St | 1986 |
Experimental antitumor activity of the amsacrine analogue CI-921.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Colonic Neoplasms; Disease Models, Animal; Dru | 1987 |
Comparison of in vivo and in vitro drug sensitivities of Lewis lung carcinoma and P388 leukaemia to analogues of amsacrine.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line; Drug Evaluation, Preclinical; Female; Leukemia | 1987 |
Cytokinetic resistance of Lewis lung carcinoma to cyclophosphamide and the amsacrine derivative CI-921.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cyclophosphamide; Drug Resistance; | 1986 |
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Cells, Cultured; DNA; DNA Repair; Etoposide; Humans; Lung | 1985 |
Schedule dependence of activity of the amsacrine analogue CI-921 towards P388 leukaemia and Lewis lung carcinoma.
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Ad | 1985 |